• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管性血友病的发病机制、临床表现及治疗

Pathogenesis, clinical picture and treatment of von Willebrand's disease.

作者信息

Lethagen S R

机构信息

Department for Coagulation Disorders, University of Lund, Malmö, Sweden.

出版信息

Ann Med. 1995 Dec;27(6):641-51. doi: 10.3109/07853899509019250.

DOI:10.3109/07853899509019250
PMID:8652143
Abstract

Von Willebrand's disease is probably the most common congenital bleeding disorder, with a prevalence close to 1% in some epidemiological studies. The disease is caused by a quantitative deficiency or a qualitative defect of the von Willebrand factor, which is a multimeric glycoprotein consisting of subunits of 2050 amino acids. The size of multimers ranges from approximately 500 kDa to 20 MDa. Each subunit consist of repeated domain structures. Several functional domains have been identified which can bind such structures as platelet receptors glycoprotein Ib or IIb/IIIA, heparin, collagen or factor VIII. The von Willebrand factor has two main functions in haemostasis, to promote normal platelet adhesion and to be a carrier protein for factor VIII. Von Willebrand's disease is divided into three major types and several subtypes depending on the quantity and quality of the von Willebrand factor in plasma and platelets. A new classification has recently been proposed. Typical symptoms are mucosal bleeding, easy bruising and increased bleeding tendency in connection with tooth extractions and other invasive procedures. Severe cases may have joint bleeding and other haemophilia-like bleeding. Desmopressin is the treatment of choice in mild cases, whereas more severe cases need treatment with factor VIII concentrates.

摘要

血管性血友病可能是最常见的先天性出血性疾病,在一些流行病学研究中的患病率接近1%。该病由血管性血友病因子的数量不足或质量缺陷引起,血管性血友病因子是一种由2050个氨基酸亚基组成的多聚体糖蛋白。多聚体的大小范围约为500 kDa至20 MDa。每个亚基由重复的结构域组成。已鉴定出几个功能结构域,它们可以结合血小板受体糖蛋白Ib或IIb/IIIA、肝素、胶原蛋白或因子VIII等结构。血管性血友病因子在止血中有两个主要功能,促进正常血小板黏附以及作为因子VIII的载体蛋白。根据血浆和血小板中血管性血友病因子的数量和质量,血管性血友病分为三大类型和几个亚型。最近提出了一种新的分类方法。典型症状为黏膜出血、容易瘀伤以及拔牙和其他侵入性操作时出血倾向增加。严重病例可能出现关节出血和其他类似血友病的出血。去氨加压素是轻度病例的首选治疗方法,而更严重的病例则需要用因子VIII浓缩物进行治疗。

相似文献

1
Pathogenesis, clinical picture and treatment of von Willebrand's disease.血管性血友病的发病机制、临床表现及治疗
Ann Med. 1995 Dec;27(6):641-51. doi: 10.3109/07853899509019250.
2
[Von Willebrand disease : diagnosis and management].[血管性血友病:诊断与管理]
Internist (Berl). 2010 Sep;51(9):1118, 1120-6. doi: 10.1007/s00108-009-2491-y.
3
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.2003年的血管性血友病:迈向全面鉴定基因缺陷以实现正确诊断和治疗
Haematologica. 2003 Jan;88(1):94-108.
4
Treatment of von Willebrand's Disease.血管性血友病的治疗
N Engl J Med. 2004 Aug 12;351(7):683-94. doi: 10.1056/NEJMra040403.
5
Structure and function of von Willebrand factor: relationship to von Willebrand's disease.血管性血友病因子的结构与功能:与血管性血友病的关系
Mayo Clin Proc. 1991 Aug;66(8):847-61. doi: 10.1016/s0025-6196(12)61204-x.
6
Diagnosis and management of von Willebrand's syndrome.血管性血友病的诊断与管理
Med Clin North Am. 1994 May;78(3):609-23. doi: 10.1016/s0025-7125(16)30149-3.
7
Treatment of von Willebrand's disease.血管性血友病的治疗。
J Intern Med Suppl. 1997;740:129-32.
8
Von Willebrand's disease: case report and review of literature.血管性血友病:病例报告及文献综述
Pan Afr Med J. 2017 Jun 29;27:147. doi: 10.11604/pamj.2017.27.147.12248. eCollection 2017.
9
Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.去氨加压素给药后因子VIII/血管性血友病因子的多聚体组成:对血管性血友病各亚型病理生理学和治疗的意义
Blood. 1982 Jun;59(6):1272-8.
10
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病:2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.

引用本文的文献

1
Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.在生物技术过程中使用重组 Furin 的策略:完全切割目标蛋白前体。
Cytotechnology. 1999 Jul;30(1-3):1-16. doi: 10.1023/A:1008030407679.